In general, routine annual vaccination is recommended for all patients 6 months of age and older who have no contraindications and should be completed by the end of October.
COVID-19 research is expected to yield medical and scientific dividends for the treatment of influenza, cancer, cystic fibrosis, and other chronic diseases.
Although the facts in this month’s Legal Advisor predate the COVID-19 pandemic, the legal impact is likely to be relevant in cases that involve religious exemption for mandatory vaccines.
Researchers conducted a meta-analysis to determine the effectiveness of N95 respirators vs surgical masks in protecting against viral respiratory illness transmission.
The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine.
Researchers conducted a study that compared the prevalence of COVID-19 with influenza co-infection among the general population vs hospitalized patients, as well as outcomes associated with both infections vs COVID-19 alone.
As HIV-exposed, uninfected infants have higher rates of morbidity and mortality than HIV-unexposed uninfected infants, a study was conducted to analyze whether particular infections or immune responses contribute to hospitalization.
The researchers tested their hypothesis that a decrease in respiratory virus incidence would be associated with a reduction in inappropriate ambulatory antibiotic orders.
An emerging body of research highlights plant-based vaccine manufacturing as a potential solution to risks posed by traditional egg-based manufacturing.
Study authors evaluated influenza-vaccinated patients hospitalized with an influenza-like illness to identify characteristics associated with being at increased risk for hospitalization with influenza.
